Celgene's Pomalyst is expected to get FDA approval soon. Does it present a competitive threat to Carfi? I recognize their underlying mechanisms are different. However, they both target relapsed patients.
Both the FDA and the European Medicines Agency (EMA) are reviewing applications for the approval of Pomalyst in combination with Dexamethasone for the treatment of RRMM patients who have received at least 2 prior therapies. Pomalyst belongs to the same class of drugs as Revlimid (Lenalidomide) and Thalomid (Thalidomide), which are 2 orphan drugs that Celgene already markets as MM treatments in the US and internationally. Thus, Celgene currently has a strong presence in the MM market. Pomalyst will be extending the company’s leadership position in MM.